Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 673

1.

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.

Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan GJ, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD.

Am J Gastroenterol. 2018 Jul 19. doi: 10.1038/s41395-018-0202-9. [Epub ahead of print]

PMID:
30022113
2.

Obesity is Independently Associated with Higher Annual Burden and Costs of Hospitalization in Patients with Inflammatory Bowel Diseases.

Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S.

Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30703-1. doi: 10.1016/j.cgh.2018.07.004. [Epub ahead of print]

PMID:
30012429
3.

A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease.

Sandborn WJ, Abreu MT, Dubinsky MC.

Gastroenterol Hepatol (N Y). 2018 May;14(5 Suppl 2):1-12.

4.

Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.

Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F.

Inflamm Bowel Dis. 2018 Jul 6. doi: 10.1093/ibd/izy229. [Epub ahead of print]

PMID:
29982631
5.

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Jun 27. doi: 10.1038/s41395-018-0162-0. [Epub ahead of print]

PMID:
29946178
6.

No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ.

Am J Gastroenterol. 2018 Jun 21. doi: 10.1038/s41395-018-0144-2. [Epub ahead of print]

PMID:
29925913
7.

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.

Singh S, Fumery M, Sandborn WJ, Murad MH.

Aliment Pharmacol Ther. 2018 Jun 19. doi: 10.1111/apt.14852. [Epub ahead of print] Review.

PMID:
29920733
8.

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.

Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2018 Aug;48(3):347-357. doi: 10.1111/apt.14853. Epub 2018 Jun 19.

PMID:
29920726
9.

Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.

Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C.

J Crohns Colitis. 2018 Jun 18. doi: 10.1093/ecco-jcc/jjy079. [Epub ahead of print]

PMID:
29917070
10.

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2 Study.

Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C; Peficitinib-UC Study Group.

J Crohns Colitis. 2018 Jun 15. doi: 10.1093/ecco-jcc/jjy085. [Epub ahead of print]

PMID:
29917064
11.

Efficacy of Ustekinumab in Inducing Endoscopic Healing in Patients with Crohn's Disease.

Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ.

Gastroenterology. 2018 Jun 14. pii: S0016-5085(18)34655-9. doi: 10.1053/j.gastro.2018.06.035. [Epub ahead of print]

PMID:
29909019
12.

Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease.

Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J.

Inflamm Bowel Dis. 2018 Jun 8. doi: 10.1093/ibd/izy214. [Epub ahead of print]

PMID:
29889233
13.

Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials.

Singh S, Proudfoot J, Xu R, Sandborn WJ.

Am J Gastroenterol. 2018 Jun;113(6):883-889. doi: 10.1038/s41395-018-0104-x. Epub 2018 Jun 5.

PMID:
29867171
14.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 May 29. pii: S0016-5085(18)34572-4. doi: 10.1053/j.gastro.2018.05.039. [Epub ahead of print]

PMID:
29857091
15.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

16.

Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.

Hemperly A, Sandborn WJ, Vande Casteele N.

Inflamm Bowel Dis. 2018 May 17. doi: 10.1093/ibd/izy189. [Epub ahead of print]

PMID:
29788338
17.

Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.

Singh S, Proudfoot J, Xu R, Sandborn WJ.

Inflamm Bowel Dis. 2018 May 18. doi: 10.1093/ibd/izy135. [Epub ahead of print]

PMID:
29788260
18.

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS.

Inflamm Bowel Dis. 2018 May 18. doi: 10.1093/ibd/izy171. [Epub ahead of print]

PMID:
29788240
19.

Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.

Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ.

PLoS One. 2018 May 17;13(5):e0195123. doi: 10.1371/journal.pone.0195123. eCollection 2018.

20.

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S.

J Crohns Colitis. 2018 May 14. doi: 10.1093/ecco-jcc/jjy049. [Epub ahead of print]

PMID:
29767728

Supplemental Content

Loading ...
Support Center